Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2024-12-01 DOI:10.21873/anticanres.17379

Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka

{"title":"Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.","authors":"Kenjiro Tsuruoka, Yosuke Tamura, Yasuyuki Shimazu, Masahiro Arai, Sho Mitsuya, Tomoya Funamoto, Hiroyuki Tsuji, Ninso Matsunaga, Takahiko Nakamura, Soichiro Ikeda, Shigeru Kawabata, Akihisa Imagawa, Yasuhito Fujisaka","doi":"10.21873/anticanres.17379","DOIUrl":null,"url":null,"abstract":"Background/aim: Few studies have examined the association between programmed cell death ligand 1 (PD-L1) expression in small cell lung cancer and the effect of chemoimmunotherapy.Patients and methods: Patients diagnosed with extensive-stage small cell lung cancer at our hospital between September 2019 and August 2023, who were treated with atezolizumab plus carboplatin and etoposide and had pathological tissue immunostained with SP142, were retrospectively examined to determine whether treatment efficacy differed depending on the expression of PD-L1.Results: Twenty-nine patients were analyzed. SP142 immunostaining revealed that the tumor cell (TC) score was 3, 2, 1, and 0 in 1, 0, 0, and 28 cases, respectively. The tumor-infiltrating cell (IC) score was 3, 2, 1, and 0 in 1, 0, 5, and 23 cases, respectively. The median progression-free survival (PFS) of the patients who tested positive and negative for TC was 13 and 5 months, respectively [hazard ratio (HR)=0.041; 95% confidence interval (CI)=0.000-36.225; p=0.109]; and the median overall survival (OS) was 13 and 7.5 months (HR=0.046; 95%CI=0.000-948.833; p=0.338), respectively. The median PFS of the patients who tested positive and negative for IC was 8 and 4 months, respectively (HR=0.216; 95%CI=0.061-0.765; p=0.004); the median OS was 15 and 8 months, respectively (HR=0.573; 95%CI=0.168-1.955; p=0.346).Conclusion: Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5531-5539"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Few studies have examined the association between programmed cell death ligand 1 (PD-L1) expression in small cell lung cancer and the effect of chemoimmunotherapy.

Patients and methods: Patients diagnosed with extensive-stage small cell lung cancer at our hospital between September 2019 and August 2023, who were treated with atezolizumab plus carboplatin and etoposide and had pathological tissue immunostained with SP142, were retrospectively examined to determine whether treatment efficacy differed depending on the expression of PD-L1.

Results: Twenty-nine patients were analyzed. SP142 immunostaining revealed that the tumor cell (TC) score was 3, 2, 1, and 0 in 1, 0, 0, and 28 cases, respectively. The tumor-infiltrating cell (IC) score was 3, 2, 1, and 0 in 1, 0, 5, and 23 cases, respectively. The median progression-free survival (PFS) of the patients who tested positive and negative for TC was 13 and 5 months, respectively [hazard ratio (HR)=0.041; 95% confidence interval (CI)=0.000-36.225; p=0.109]; and the median overall survival (OS) was 13 and 7.5 months (HR=0.046; 95%CI=0.000-948.833; p=0.338), respectively. The median PFS of the patients who tested positive and negative for IC was 8 and 4 months, respectively (HR=0.216; 95%CI=0.061-0.765; p=0.004); the median OS was 15 and 8 months, respectively (HR=0.573; 95%CI=0.168-1.955; p=0.346).

Conclusion: Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.